• Vol. 35 No. 2, 96–99
  • 15 February 2006

The Risk of Suicidality with Selective Serotonin Reuptake Inhibitors

150



150 Views
23 Downloads

Download PDF

ABSTRACT

Antidepressants are efficacious in the treatment of depression but they are not without side effects. The recent findings on the risk of suicide with selective serotonin reuptake inhibitor treatment, however, have raised serious concerns about the risk-benefit ratio of their use. The development of the concerns is traced and the risks discussed, particularly in the child and adolescent group. The prescriber needs to be aware of the issues and of the need for close clinical monitoring of patients started on selective serotonin reuptake inhibitor treatment.


The first antidepressants were discovered 50 years ago by chance. Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) dominated the treatment of depression from the late 1950s until the late 1980s, when selective serotonin reuptake inhibitors (SSRIs) were introduced.

This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.